The National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli) has signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim India Pvt. Ltd to strengthen academic and research collaboration across pharmaceutical technologies and innovation-driven drug development.
The announcement coincided with the launch of Cohort 2 of AMRITVA (Alliance for Medicinal Research, Innovation, Translation & Value Acceleration) — an initiative aimed at translating academic research into commercially viable pharmaceutical products and entrepreneurial ventures.
The agreement establishes a structured framework for collaboration in:
The partnership also covers NIPER Raebareli’s Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), reinforcing the focus on advanced formulation science.
As part of the collaboration, Boehringer Ingelheim India will provide researchers access to its opnMe open science platform, enabling broader scientific exchange and accelerating innovation in healthcare.
AMRITVA is implemented by the Startup Incubation and Innovation Centre, IIT Kanpur (SIIC, IIT Kanpur) in partnership with NIPER Raebareli. The initiative is supported under Corporate Social Responsibility (CSR) funding by Boehringer Ingelheim India.
The programme is designed to:
Under Cohort 2:
The funding aims to facilitate the commercialisation of promising research outcomes.
The MoU signing ceremony was attended by senior officials from the Department of Pharmaceuticals.
Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, emphasised the importance of collaborative partnerships in strengthening the research-to-market pipeline. He highlighted that such initiatives are critical for:
Other dignitaries present included Awadhesh Kumar Choudhary, Senior Economic Advisor; Anugraha P, Director, Department of Pharmaceuticals; and Dr. Ashutosh Agnihotri, CEO of SIIC, IIT Kanpur.
The Department of Pharmaceuticals continues to support the sector’s transition from a volume-driven to a value-driven growth model.
Key pillars of this shift include:
These efforts align with the broader national vision of Viksit Bharat 2047, positioning innovation and translational research as central to India’s long-term pharmaceutical competitiveness.
The MoU between NIPER Raebareli and Boehringer Ingelheim India, combined with the launch of AMRITVA Cohort 2, reflects a structured attempt to build stronger bridges between academic discovery and market-ready healthcare solutions.
By integrating institutional research, incubation support, and industry platforms such as opnMe, the partnership aims to accelerate innovation while nurturing the next generation of pharmaceutical entrepreneurs in India.